Recipharm Advanced Bio Is Advancing RNA Therapeutics

Recipharm Advanced Bio is redefining how RNA vaccines and therapeutics are manufactured by transforming a screening initiative into a predictive process-design platform. Its refined T7 polymerase library now guides construct-specific enzyme selection that:

• Lowers dsRNA impurities

• Cuts capping reagent costs

• Streamlines GMP implementation 

This is advancing the next generation of scalable, data-driven RNA production.